Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.550
Bid (Size) 5.200 (1)
Ask (Size) 5.700 (2)
Prev. Close 5.550
Today's Range 5.550 - 5.550
52wk Range 3.785 - 14.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy
Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application. 
Via Stocktwits
Exposures Product Safety
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-38.3%
-38.3%
1 Month
+11.7%
+11.7%
3 Month
-49.4%
-49.4%
6 Month
+14.7%
+14.7%
1 Year
-35.1%
-35.1%

More News

Read More
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish
Via Stocktwits
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Present at Upcoming Investor Conferences
From Candel Therapeutics
Via GlobeNewswire
Top movers in Wednesday's after hours session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
Via Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On?
Via Benzinga
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
Via Stocktwits
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
From Candel Therapeutics
Via GlobeNewswire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Via Stocktwits
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Major Indexes Falter; Dow Drops Over 550 Points
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
Via Stocktwits

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?
Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
What is the current price of Candel Therapeutics, Inc. - Common Stock?
The current price of Candel Therapeutics, Inc. - Common Stock is 5.550
When was Candel Therapeutics, Inc. - Common Stock last traded?
The last trade of Candel Therapeutics, Inc. - Common Stock was at 06/05/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.